A mole you have had since childhood or early adulthood can, in fact, turn into melanoma. Roughly four in ten melanomas show remnants of a pre-existing mole when examined under a microscope, meaning the cancer grew directly out of what was once a harmless spot. The remaining melanomas appear on previously clear skin. That split tells you something important: your old moles deserve attention, but they are not the only place trouble starts, and most moles will never become dangerous at all.
How Often Moles Actually Become Melanoma
A large study examining the origin of melanomas found that about 42% arose from a pre-existing mole (called a nevus), 34% appeared on skin with no prior mole, and 24% were uncertain either way.1British Journal of Dermatology. Melanomas arising from naevi and de novo melanomas — does origin matter? So while the answer to the title question is yes, it is worth keeping in perspective: most melanomas do not clearly come from a pre-existing mole, and the vast majority of moles on your body will never undergo a malignant change. The average adult has somewhere between 10 and 40 common moles, yet melanoma remains relatively uncommon. The lifetime risk of developing melanoma for a fair-skinned person in countries with high sun exposure is roughly 2-3%.
Histologic studies have also found differences between melanomas that grow out of moles and those that arise on clear skin. Nevus-associated melanomas tend to develop on skin with less chronic sun damage compared to de novo melanomas.2Journal of Investigative Dermatology. Factors Related to Nevus-Associated Cutaneous Melanoma: A Case-Case Study This suggests they follow a somewhat different biological path, one where the mole itself is the starting point rather than decades of cumulative ultraviolet exposure on aging skin.
Why Most Moles Stay Harmless
Common moles carry a built-in safety brake. Many harbor the same gene mutation found in melanoma, a change in the BRAF gene that in theory should drive runaway cell growth. Yet the mole sits on your skin for decades without doing anything alarming. The reason is that the mutation triggers a self-defense response in the cells: they essentially shut themselves down and stop dividing, entering a state of permanent growth arrest.3PubMed Central. The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytes This growth arrest is what makes a mole a mole rather than a tumor. The cells are alive but frozen in place.
Research has refined our understanding of exactly what keeps those cells dormant. There is strong evidence that cells in common acquired moles are largely in this arrested state, and that the arrest is primarily driven by shortened, dysfunctional structures at the ends of their chromosomes rather than solely by the oncogene mutation itself.4Pigment Cell & Melanoma Research. Review: Are moles senescent? Think of it as two locks on the same door. The mutation flips one lock, and the chromosome damage flips the other, together keeping the cell from re-entering the growth cycle. A small non-dormant subpopulation may persist within a mole, but as long as those cells are kept in check by the body’s other defenses, the mole remains benign.
How the Safety Brake Fails
For a mole to become cancerous, additional genetic damage has to accumulate that overrides the growth arrest. Mouse models and human tissue studies have shown that a meaningful proportion of melanomas develop from previously growth-arrested moles carrying the BRAF mutation, confirming that the dormancy process is reversible under the right (or wrong) circumstances.5Cancer Cell. Modeling Melanoma Initiation and Progression in the Mouse Additional mutations in tumor-suppressor genes, particularly those controlling the cell’s DNA-repair pathways, can unlock that door. Loss of a functional p53 gene is one well-studied example: when BRAF activation and p53 loss occur together in human melanocytes, the cells can bypass the growth arrest that would otherwise keep them dormant.3PubMed Central. The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytes
Ultraviolet radiation is the most common environmental source of that additional genetic damage. Years of sun exposure generate mutations throughout the skin, and occasionally one of those mutations hits the right gene in the right cell inside an existing mole. This is a low-probability event per mole, which is why the overwhelming majority of your moles stay benign. But it is not a zero-probability event, and it explains why dermatologists care about changes in long-standing moles rather than dismissing them as “already done growing.”
Which Moles Carry Higher Risk
Not all moles start with the same baseline risk. Two categories stand out as worth knowing about.
Congenital melanocytic nevi are moles present at birth or appearing in the first weeks of life. Their melanoma risk depends heavily on size. The largest congenital moles, those 40 centimeters or more in diameter, carry the highest risk of developing melanoma and the highest rate of fatal outcomes.6PubMed. Melanoma risk in congenital melanocytic naevi: a systematic review In children, the melanoma risk tracks with how severe the congenital condition is.7PubMed Central. Melanoma in congenital melanocytic naevi Small congenital moles, which are far more common, carry much less risk, though they still warrant routine monitoring.
Atypical (dysplastic) moles are acquired moles that look slightly unusual: larger than typical, with irregular borders or uneven coloring. Having many of these, a pattern sometimes called atypical mole syndrome, is considered the strongest phenotypic risk factor for developing melanoma.8PubMed Central. Atypical mole syndrome and dysplastic nevi: identification of populations at risk for developing melanoma – review article The risk here is partly about the moles themselves and partly about what they signal: a person whose body generates atypical moles has a melanocyte biology that is generally more prone to abnormal growth, so they need closer surveillance of all their skin, not just individual suspicious spots.
Hereditary Risk and CDKN2A Mutations
A fraction of melanoma cases cluster in families due to inherited gene mutations, most notably in a gene called CDKN2A. Among all melanoma patients, roughly 7-15% report a positive family history, but only about 5-10% have true hereditary melanoma, and just around 2% carry an identifiable CDKN2A mutation.9Australasian Journal of Plastic Surgery. The management of hereditary melanoma, FAMMM syndrome and germline CDKN2A mutations: a narrative review For those who do carry the mutation, the risk is substantial. Estimates of lifetime melanoma risk for CDKN2A carriers vary widely depending on geography and sun exposure; one Australian study put the risk at about 20% by age 50 and 52% by age 80, while an older consortium estimate placed it as high as 91% over a lifetime in Australian populations.9Australasian Journal of Plastic Surgery. The management of hereditary melanoma, FAMMM syndrome and germline CDKN2A mutations: a narrative review
If you have two or more close relatives who have had melanoma, or if you have a personal history of multiple melanomas, genetic counseling may be worth discussing with your doctor. Carriers of these mutations typically have many moles, many of them atypical, and their surveillance schedule is more intensive than for the general population.
Changes Worth Paying Attention To
The ABCDE framework has been a standard teaching tool for decades: Asymmetry, Border irregularity, Color variation, Diameter over 6 millimeters, and Evolution (change over time). Studies have shown this paradigm helps with early melanoma detection in clinical exams and public education.10PubMed. The evolution of melanoma diagnosis: 25 years beyond the ABCDs The “E” is arguably the most important letter for the question of longstanding moles: a mole that has looked the same for 20 years and then starts changing shape, color, or size is behaving differently, and that behavioral shift is what needs evaluation.
But the ABCDE criteria have limitations. Some melanomas do not look like textbook melanomas at all. A study classifying melanoma by appearance found five distinct visual patterns, including a cluster that mimicked harmless-looking moles and another that resembled the crusty, waxy growths called seborrheic keratoses.11Journal of the American Academy of Dermatology. Clinical spectrum of cutaneous melanoma morphology The mole-like melanomas were found in younger patients and tended to be thinner, while those mimicking other skin growths were thicker and more aggressive by the time they were caught. Seborrheic keratosis-like melanomas are an especially tricky diagnostic challenge because they combine features that point both toward and away from melanoma on close examination.12Melanoma Research. Seborrheic keratosis-like melanoma: a diagnostic challenge
The practical takeaway is that the ABCDE rules are a good starting point, but relying on them alone means some melanomas will fly under the radar. Any new or changing skin lesion that catches your attention, even if it does not check the classic boxes, is worth showing a dermatologist.
Mole Changes That Aren’t Cancer
Moles can change for benign reasons, and pregnancy is a common context. Hormonal shifts during pregnancy can cause moles to darken, enlarge, or develop new pigment patterns. The relationship between pregnancy and actual melanoma risk is debated: some researchers have proposed that hormonal changes and immune shifts during pregnancy increase susceptibility, but the evidence remains inconclusive.13PubMed. Changes in Melanocytic Nevi and Melanoma Associated With Pregnancy: A Scoping Review One case-control study did find that women who reported changes in their moles during recent pregnancies had roughly three times the odds of being diagnosed with melanoma, though that estimate was based on small numbers.14American Journal of Epidemiology. Reproductive Risk Factors for Cutaneous Melanoma in Women: A Case-Control Study
The upshot for pregnant people is that mole changes during pregnancy are common and usually harmless, but they should still be mentioned to a doctor, especially if a mole changes asymmetrically, develops very irregular borders, or keeps evolving after delivery. The difficulty is that normal pregnancy-related darkening can look alarming, and genuinely concerning changes can be dismissed as “just pregnancy hormones.” Erring on the side of having a dermatologist look is the safer choice.
Beyond pregnancy, moles can also change with age, weight gain or loss, sun exposure, and even friction from clothing. A mole that gradually fades over decades is likely undergoing a normal aging process. One that develops a new bump, bleeds without being scratched, or grows a satellite lesion nearby is more concerning.
Why People Put Off Getting Moles Checked
One of the most frustrating aspects of melanoma prevention is that people often notice changes in their moles but do not seek care. A qualitative study of patients found that changing moles are frequently perceived as trivial and not associated with possible skin cancer.15PubMed Central. Patient understanding of moles and skin cancer, and factors influencing presentation in primary care: a qualitative study People rationalize: the mole has been there forever, it is probably fine, it is just getting a little bigger with age. Social barriers matter too: embarrassment about a spot on an intimate body area, difficulty getting a dermatology appointment, or the assumption that skin cancer is something that only happens to very sun-damaged skin.
The finding that people dismiss mole changes as trivial is especially important in light of how melanoma grows out of existing moles. The very moles people have grown accustomed to, spots they have known their whole lives, are the ones they are least likely to scrutinize. Familiarity breeds complacency. Dermatologists sometimes recommend taking dated photos of your moles so you have something concrete to compare against rather than relying on memory, which is unreliable for slow changes.
Digital Monitoring and Smartphone Apps
Dermatologists who manage high-risk patients, such as those with atypical mole syndrome or a family history of melanoma, now commonly use digital dermoscopy combined with total-body photography. These programs photograph all of a patient’s moles at baseline and then compare them digitally at follow-up visits. The approach has been shown to improve early diagnosis and diagnostic accuracy.16Medical Journals / Acta Dermato-Venereologica. Dermoscopy, Digital Dermoscopy and Other Diagnostic Tools in the Early Detection of Melanoma and Follow-up of High-risk Skin Cancer Patients By having a visual record, the dermatologist can spot subtle changes that neither the patient nor the doctor would notice from memory alone.
Consumer-facing smartphone apps that claim to assess skin cancer risk are a different story. A study of commercially available apps found that their average sensitivity for detecting melanoma was only about 28%, meaning they missed roughly seven out of ten melanomas. Mean accuracy across the apps was around 59%.17PubMed Central. Accuracy of commercially available smartphone applications for the detection of melanoma One app, SkinVision, performed somewhat better in a separate systematic review, reaching about 80% sensitivity for malignant or premalignant lesions, though specificity was about 78%, meaning it also flagged a fair number of benign spots as suspicious.18PubMed. Algorithm based smartphone apps to assess risk of skin cancer in adults: systematic review of diagnostic accuracy studies The gap between clinical-grade digital dermoscopy and consumer apps remains large. Using an app to photograph and track your moles over time is reasonable as a personal habit, but trusting an app’s “low risk” rating as a reason not to see a doctor is dangerous.
The Overdiagnosis Problem
There is a growing conversation in dermatology about whether increased surveillance is catching melanomas that would never have caused harm. In fair-skinned populations subjected to intensive screening, diagnoses of thin and in situ melanomas have risen sharply over recent decades, yet rates of advanced melanoma and melanoma-related death have not fallen in proportion.19PubMed. Mole or Early Melanoma? Rethinking Early Detection, Overdiagnosis, and the Benign-Malignant Paradigm This pattern is consistent with overdiagnosis: detecting biologically sluggish growths that share clinical and microscopic features with aggressive tumors but would never have progressed to dangerous disease.
The core difficulty is that pathologists examining a borderline lesion under the microscope cannot always tell whether it will behave aggressively or sit harmlessly for decades. The traditional framework classifies every melanocytic lesion as either benign or malignant, but many lesions sit in a gray zone. Some researchers have argued for shifting toward a risk-based diagnostic framework that would acknowledge uncertainty rather than forcing a binary label, which could reduce unnecessary excisions and the anxiety that comes with a cancer diagnosis for lesions that posed little real threat.19PubMed. Mole or Early Melanoma? Rethinking Early Detection, Overdiagnosis, and the Benign-Malignant Paradigm
This does not mean you should ignore a changing mole. Thick melanomas that are caught late still carry a serious prognosis, and catching an aggressive melanoma early saves lives. The overdiagnosis debate is more about how the medical system handles the ambiguous cases, those thin lesions that might be early melanoma or might be a mole that has wandered slightly off the normal path without ever posing a threat. For an individual patient, the cautious move is still to get a suspicious spot evaluated. But understanding this debate helps explain why a biopsy result might come back with hedging language or why a dermatologist might recommend “watchful waiting” for a borderline lesion rather than immediate surgery. The science of telling a harmless mole from a dangerous one is genuinely harder than most people assume, and the field is still working out the best way to handle that uncertainty.